-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Looking back on the past, looking forward to the future
.
On the occasion of the arrival of 2022, Yimaitong Hematology launched the "Annual Inventory" series of articles, summarizing the research frontiers and guideline trends worthy of attention in the field of blood diseases in 2021
.
Today, we bring you a summary of acute lymphoblastic leukemia related content, click the title of the article to read the original text
.
New Drug Progress 01 Traditional Drugs 1.
2021 ASH | Third-generation TKI combined with chemotherapy, Ph-positive ALL benefits better? The final results of the Ponalfil study will answer you 2.
Calaspargase may be an alternative to pegaspargase for the treatment of newly diagnosed ALL or LBL children and adolescents 3.
The exposure dose of asparaginase is significantly associated with the risk of ALL recurrence in children 4.
The latest COG research results: Reducing the frequency of pulsed administration of vincristine and dexamethasone in children with standard-risk B-ALL can achieve excellent therapeutic effects Come to New Dawn 2.
2021 SOHO Celebrities Commentary | Prof.
Liu Jiajun interprets the treatment prospects of belintoumab combined with pembrolizumab in R/R ALL 3.
Interpretation of JAMA | Prof.
Shen Shuhong: belintoumumab Anti-consolidation therapy significantly prolongs EFS and improves transplant prognosis in children with high-risk first-relapse B-ALL Extending survival 5.
When medical insurance is in progress | Care for ALL: Belintoumumab helps patients with relapsed or refractory acute lymphoblastic leukemia to open the era of immunotherapy 03 Antibody-drug conjugates (ADC) 1.
2021 ASH first looktarget To CD22 ADC ADCT-602 Phase 1 Trial Results in Adult Patients with Relapsed or Refractory CD22+ B-ALL Coffee Talk | Prof.
Zhang Mingming: Challenges and research progress of CAR-T in the treatment of T-ALL/LBL how to respond? 3.
FDA update | Approved brexucabtagene autoleucel for the treatment of patients with relapsed and refractory precursor B-cell acute lymphoblastic leukemia 4.
Relapsed B-ALL after Allo-SCT is expected to usher in a new treatment method-donor-derived CAR-T cells 5.
The novel second-generation CD19 CAR-T has excellent efficacy and controllable safety in R/R B-ALL 6.
Prognosis exploration of adult R/R B-ALL patients who progressed after CD19 CAR-T therapy 7.
2021 EHA Prospect | CD22-CAR-T cell therapy for adult R/R B-ALL8.
2021 ASH1-year follow-up results of CNCT19 in pediatric and adult R/R B-ALL patients9.
Pediatric and adolescent R/R ALL patients Welcome to the new hope of cure, long-term follow-up data reveal the survival of CAR-T therapy bridging Allo-HSCT 10.
2021 EBMT | Anti-CD19 CAR-T therapy for children with R/R ALL: fractional infusion can improve safety Treatment Effectiveness 11.
How is the treatment of acute T-lymphoblastic leukemia progressing? 05Others 1.
Prof.
Dehui Zou: Advances in the treatment of acute lymphoblastic leukemia | 2021 Leukemia and Lymphoma Summit Forum 2.
2021 CSCOProfessor Gong Tiejun: Advances in the treatment of acute lymphoblastic leukemia 3.
Prof.
Ting Liu: Treatment of acute lymphoblastic leukemia New progress 4.
A new era of "chemo-free" treatment of Ph+ acute lymphoblastic leukemia? 5.
Novel cellular immunotherapy - STAR-T treatment of relapsed/refractory B-cell acute lymphoblastic leukemia Hematopoietic stem cell transplantation related progress 1.
Prof.
Zhang Xiaohui: In ALL, is the era of immunotherapy an opportunity or a challenge for allo-HSCT? The First National Academic Conference on Lymphocytic Diseases of the Chinese Medical Association 2.
Interview with a celebrity | Professor Jiang Erlie: How to further improve the efficacy of ASCT in the treatment of adult ALL? 3.
Prof.
Wang Yu: Transplantation status of ALL patients and application of new drugs 4.
International perspective | New transplantation strategies and post-transplant treatment options for ALL patients 5.
How to judge whether adult high-risk Ph-ALL needs allogeneic hematopoietic stem cell transplantation? 6.
Do MRD-negative high-risk PH-ALL patients still need transplantation? 7.
Preemptive interferon-α therapy can prevent recurrence and improve long-term survival in ALL patients after transplantation 8.
Haploid transplantation in children with MLL-r B-ALL can improve prognosis compared with chemotherapy 9.
Children with Ph-negative very high-risk B- Haploid transplantation in ALL CR1 stage with stronger chemotherapy can improve prognosis Leukemia update points 2.
Interpretation of guidelines for allogeneic transplantation for acute leukemia and MDS2021 CSCO Guidelines Conference Others 1.
.
On the occasion of the arrival of 2022, Yimaitong Hematology launched the "Annual Inventory" series of articles, summarizing the research frontiers and guideline trends worthy of attention in the field of blood diseases in 2021
.
Today, we bring you a summary of acute lymphoblastic leukemia related content, click the title of the article to read the original text
.
New Drug Progress 01 Traditional Drugs 1.
2021 ASH | Third-generation TKI combined with chemotherapy, Ph-positive ALL benefits better? The final results of the Ponalfil study will answer you 2.
Calaspargase may be an alternative to pegaspargase for the treatment of newly diagnosed ALL or LBL children and adolescents 3.
The exposure dose of asparaginase is significantly associated with the risk of ALL recurrence in children 4.
The latest COG research results: Reducing the frequency of pulsed administration of vincristine and dexamethasone in children with standard-risk B-ALL can achieve excellent therapeutic effects Come to New Dawn 2.
2021 SOHO Celebrities Commentary | Prof.
Liu Jiajun interprets the treatment prospects of belintoumab combined with pembrolizumab in R/R ALL 3.
Interpretation of JAMA | Prof.
Shen Shuhong: belintoumumab Anti-consolidation therapy significantly prolongs EFS and improves transplant prognosis in children with high-risk first-relapse B-ALL Extending survival 5.
When medical insurance is in progress | Care for ALL: Belintoumumab helps patients with relapsed or refractory acute lymphoblastic leukemia to open the era of immunotherapy 03 Antibody-drug conjugates (ADC) 1.
2021 ASH first looktarget To CD22 ADC ADCT-602 Phase 1 Trial Results in Adult Patients with Relapsed or Refractory CD22+ B-ALL Coffee Talk | Prof.
Zhang Mingming: Challenges and research progress of CAR-T in the treatment of T-ALL/LBL how to respond? 3.
FDA update | Approved brexucabtagene autoleucel for the treatment of patients with relapsed and refractory precursor B-cell acute lymphoblastic leukemia 4.
Relapsed B-ALL after Allo-SCT is expected to usher in a new treatment method-donor-derived CAR-T cells 5.
The novel second-generation CD19 CAR-T has excellent efficacy and controllable safety in R/R B-ALL 6.
Prognosis exploration of adult R/R B-ALL patients who progressed after CD19 CAR-T therapy 7.
2021 EHA Prospect | CD22-CAR-T cell therapy for adult R/R B-ALL8.
2021 ASH1-year follow-up results of CNCT19 in pediatric and adult R/R B-ALL patients9.
Pediatric and adolescent R/R ALL patients Welcome to the new hope of cure, long-term follow-up data reveal the survival of CAR-T therapy bridging Allo-HSCT 10.
2021 EBMT | Anti-CD19 CAR-T therapy for children with R/R ALL: fractional infusion can improve safety Treatment Effectiveness 11.
How is the treatment of acute T-lymphoblastic leukemia progressing? 05Others 1.
Prof.
Dehui Zou: Advances in the treatment of acute lymphoblastic leukemia | 2021 Leukemia and Lymphoma Summit Forum 2.
2021 CSCOProfessor Gong Tiejun: Advances in the treatment of acute lymphoblastic leukemia 3.
Prof.
Ting Liu: Treatment of acute lymphoblastic leukemia New progress 4.
A new era of "chemo-free" treatment of Ph+ acute lymphoblastic leukemia? 5.
Novel cellular immunotherapy - STAR-T treatment of relapsed/refractory B-cell acute lymphoblastic leukemia Hematopoietic stem cell transplantation related progress 1.
Prof.
Zhang Xiaohui: In ALL, is the era of immunotherapy an opportunity or a challenge for allo-HSCT? The First National Academic Conference on Lymphocytic Diseases of the Chinese Medical Association 2.
Interview with a celebrity | Professor Jiang Erlie: How to further improve the efficacy of ASCT in the treatment of adult ALL? 3.
Prof.
Wang Yu: Transplantation status of ALL patients and application of new drugs 4.
International perspective | New transplantation strategies and post-transplant treatment options for ALL patients 5.
How to judge whether adult high-risk Ph-ALL needs allogeneic hematopoietic stem cell transplantation? 6.
Do MRD-negative high-risk PH-ALL patients still need transplantation? 7.
Preemptive interferon-α therapy can prevent recurrence and improve long-term survival in ALL patients after transplantation 8.
Haploid transplantation in children with MLL-r B-ALL can improve prognosis compared with chemotherapy 9.
Children with Ph-negative very high-risk B- Haploid transplantation in ALL CR1 stage with stronger chemotherapy can improve prognosis Leukemia update points 2.
Interpretation of guidelines for allogeneic transplantation for acute leukemia and MDS2021 CSCO Guidelines Conference Others 1.
